QdotPharma

Qdot Pharma is a clinical-stage biotechnology company based in South Korea that specializes in the development of next-generation bispecific antibodies for oncology. The company utilizes its proprietary "Q-Body" platform to create "4-1BB-based" bispecific antibodies that aim to stimulate the immune system specifically within the tumor microenvironment, thereby reducing systemic toxicity. Its lead candidate, QD101, targets both HER2 and 4-1BB and is designed to treat patients with HER2-positive solid tumors who have progressed on standard therapies. Qdot Pharma's pipeline also includes programs targeting Claudin 18.2 and other tumor-associated antigens. The company is focused on addressing unmet medical needs in the field of immuno-oncology through precision protein engineering.